News
BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has ...
Zacks Investment Research on MSN1d
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Pfizer PFE has strengthened its R&D pipeline through M&A deals and clinical trial success over the past decade. Pfizer has ...
Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion. Click here to find out why PFE stock is a Buy.
BridgeBio Pharma (BBIO) alleges that Pfizer (PFE) and Alnylam Pharma (ALNY) have used questionable methods to promote their ...
Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking ...
Thinking about what to do with your Pfizer shares? You are definitely not alone, especially as sentiment around the stock feels conflicted. Over the past week, Pfizer slid a modest 0.7%, and for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback